Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Cell Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SIRPB2 drug discovery. SIRPB2 (Signal-regulatory protein beta-2) represents an emerging node in CD47-mediated myeloid regulation, coupling with DAP12 to deliver activating signals distinct from the inhibitory SIRPA axis. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SIRPB2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. HEK293 expressed for native glycosylation. Sequence Verified. Theoretical MW confirmed. |
View SIRPB2 Products |
| Gene Delivery | SIRPB2 Lentivirus Particles (Full-length ORF) Full-length ORF for stable cell lines. Preserve conformation for DAP12 coupling and functional assays. |
View SIRPB2 Products |
| Benchmark Ab | Anti-SIRPB2 Reference Antibody Recombinant monoclonal for assay validation, SPR positive control, and epitope mapping. |
View SIRPB2 Products |
| Validator | SIRPB2 siRNA Set Gene-specific knockdown for specificity verification in cellular assays. |
View SIRPB2 Products |
| Related Target: SIRPA | SIRPA (CD172a) Inhibitory counterpart; essential for selectivity counter-screening and dual-target modulation strategies. |
View SIRPA Products |
| Related Target: CD47 | CD47 Primary ligand for SIRPB2; required for competitive binding and blocking assays. |
View CD47 Products |
| Related Target: TYROBP | TYROBP (DAP12) Signaling adapter partner; pathway validation for activation mechanism studies. |
View TYROBP Products |
| Related Target: SIRPG | SIRPG Closest SIRP family member for orthogonal specificity validation and off-target liability assessment. |
View SIRPG Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SIRP Family Cross-Reactivity (SIRPA/SIRPB1/SIRPG) | Strictly sequence-verified homolog panel proteins (SIRPA, SIRPB1, SIRPG) produced with >95% purity for precise SPR counter-screening. |
| DAP12 Coupling Signaling (Need functional readout for agonist screening) | Lentivirus-expressed full-length SIRPB2 preserves native conformation and DAP12 association; compatible with NFAT reporter systems. |
| Loss of Native Epitopes in Recombinant Format | HEK293 expressed ECD-Fc fusion proteins ensure native mammalian glycosylation and correct theoretical MW. |
| Cross-species Cyno/Mouse Evaluation (Preclinical translation) | Human/Cynomolgus/Mouse SIRPB2 ECD-Fc proteins available with matched purity specifications (>95%) for species cross-reactivity panels. |
| Ligand Competition (vs CD47) | High-purity CD47 protein available for SPR/BLI competition assays; endotoxin-controlled for cellular binding studies. |
Live SIRPB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SIRPB2 therapeutics is intensifying as researchers recognize its distinct role from SIRPA in myeloid cell activation. While the first-generation CD47-SIRPA axis dominates current clinical pipelines, it faces hematological toxicities (anemia, antigen sink) and limited efficacy in solid tumors. SIRPB2, through DAP12-coupled activation signaling, offers a counter-regulatory mechanism with potential to reprogram the tumor microenvironment without erythrocyte depletion. Current development focuses on agonistic monoclonal antibodies that can trigger tumor-associated macrophage (TAM) repolarization, and bispecific antibodies designed to engage myeloid cells selectively at the tumor site. As the field matures, the next wave of R&D aims at improving cross-species translatability and subfamily selectivity to de-risk safety liabilities ahead of IND-enabling studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonistic Monoclonal Antibodies | Emerging Biotechs, Academic Consortia | Solid Tumors (Macrophage activation) | DAP12 Reporter Assay (Need full-length lentivirus); Selectivity vs SIRPA (Need homolog panel) |
| Bispecific Antibodies (TAA x SIRPB2) | Early-stage Biotechs, Preclinical Academic Spin-offs | Solid Tumors (TME Reprogramming) | Heterodimer validation (Need high-purity, natively glycosylated ECD-Fc) |
| ADC (Antibody-Drug Conjugate) | Exploratory Programs | Immunology (Targeted depletion) | Internalization Assay (Need stable cell line via lentivirus) |
| Blocking Monoclonal Antibody | Emerging biotech, Academic labs | B-cell malignancies, Autoimmune disease | Subfamily specificity panel vs SIRPA/SIRPG (Need homolog proteins) |
| Cell Therapy (Engineered Macrophages) | Next-Gen CAR-M Developers | Immunologically Cold Solid Tumors | Receptor activation assays (Need lentivirus for target cell line construction) |
| Small Molecule Modulators | Academic Drug Discovery | Autoimmune Diseases | Binding site verification (Need mutant proteins for epitope mapping) |